Epistatic interaction between ERAP2 and HLA modulates HIV-1 adaptation and disease outcome in an Australian population.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 17 10 2023
accepted: 19 06 2024
medline: 9 7 2024
pubmed: 9 7 2024
entrez: 9 7 2024
Statut: aheadofprint

Résumé

A strong genetic predictor of outcome following untreated HIV-1 infection is the carriage of specific alleles of human leukocyte antigens (HLAs) that present viral epitopes to T cells. Residual variation in outcome measures may be attributed, in part, to viral adaptation to HLA-restricted T cell responses. Variants of the endoplasmic reticulum aminopeptidases (ERAPs) influence the repertoire of T cell epitopes presented by HLA alleles as they trim pathogen-derived peptide precursors to optimal lengths for antigen presentation, along with other functions unrelated to antigen presentation. We investigated whether ERAP variants influence HLA-associated HIV-1 adaptation with demonstrable effects on overall HIV-1 disease outcome. Utilizing host and viral data of 249 West Australian individuals with HIV-1 subtype B infection, we identified a novel association between two linked ERAP2 single nucleotide polymorphisms (SNPs; rs2248374 and rs2549782) with plasma HIV RNA concentration (viral load) (P adjusted = 0.0024 for both SNPs). Greater HLA-associated HIV-1 adaptation in the HIV-1 Gag gene correlated significantly with higher viral load, lower CD4+ T cell count and proportion; P = 0.0103, P = 0.0061, P = 0.0061, respectively). When considered together, there was a significant interaction between the two ERAP2 SNPs and HLA-associated HIV-1 adaptation on viral load (P = 0.0111). In a comprehensive multivariate model, addition of ERAP2 haplotypes and HLA associated adaptation as an interaction term to known HLA and CCR5 determinants and demographic factors, increased the explanatory variance of population viral load from 17.67% to 45.1% in this dataset. These effects were not replicated in publicly available datasets with comparably sized cohorts, suggesting that any true global epistasis may be dependent on specific HLA-ERAP allelic combinations. Our data raises the possibility that ERAP2 variants may shape peptide repertoires presented to HLA class I-restricted T cells to modulate the degree of viral adaptation within individuals, in turn contributing to disease variability at the population level. Analyses of other populations and experimental studies, ideally with locally derived ERAP genotyping and HLA-specific viral adaptations are needed to elucidate this further.

Identifiants

pubmed: 38980912
doi: 10.1371/journal.ppat.1012359
pii: PPATHOGENS-D-23-01778
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1012359

Informations de copyright

Copyright: © 2024 Al-kaabi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Marwah Al-Kaabi (M)

School of Human Sciences, University of Western Australia, Crawley, Australia.

Pooja Deshpande (P)

School of Human Sciences, University of Western Australia, Crawley, Australia.
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.

Martin Firth (M)

School of Physics, Mathematics and Computing, Department of Mathematics and Statistics, University of Western Australia, Crawley, Australia.

Rebecca Pavlos (R)

Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.

Abha Chopra (A)

Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.

Hamed Basiri (H)

School of Human Sciences, University of Western Australia, Crawley, Australia.

Jennifer Currenti (J)

School of Human Sciences, University of Western Australia, Crawley, Australia.

Eric Alves (E)

School of Human Sciences, University of Western Australia, Crawley, Australia.

Spyros Kalams (S)

Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Jacques Fellay (J)

School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Swiss HIV Cohort Study, Zurich, Switzerland.

Elizabeth Phillips (E)

Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Simon Mallal (S)

Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Mina John (M)

School of Human Sciences, University of Western Australia, Crawley, Australia.
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia.

Silvana Gaudieri (S)

School of Human Sciences, University of Western Australia, Crawley, Australia.
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Classifications MeSH